Stock Scorer

Crinetics Pharmaceuticals, Inc. (CRNX)

Crinetics Pharmaceuticals, Inc. reported revenue of 25.1M USD for the quarter ending 30 June 2026, up 2336.3% from 1M a year earlier.

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than filled in. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD. The same series drawn ›

As last reported

The newest period the filing supports for each figure, in USD.
FigurePeriodAmountYear on year
Revenue Q2 '26 · ending 30 June 2026 25.1M +2336.3%
Gross Profit Q2 '26 · ending 30 June 2026 25M —
Operating Income Q2 '26 · ending 30 June 2026 -132.5M —
Net Income Q2 '26 · ending 30 June 2026 -120.9M —
Cost of Revenue Q2 '26 · ending 30 June 2026 154K —
Operating Cash Flow Q2 '26 · ending 30 June 2026 -94.2M —
Free Cash Flow Q2 '26 · ending 30 June 2026 -94.7M —
Shares Outstanding Q2 '26 · ending 30 June 2026 105.6M +13.4%
EPS Q2 '26 · ending 30 June 2026 -5.04 —

Revenue and profit by financial year

As filed, in USD. A year the filing does not support is not listed.
YearEnding RevenueOperating IncomeNet IncomeFree Cash Flow
20252025-12-31 7.7M-516.8M-465.3M-383.7M
20242024-12-31 1M-338.9M-298.4M-234M
20232023-12-31 4M-222.6M-214.5M-173.3M
20222022-12-31 0-167.9M-163.9M-116.9M
20212021-12-31 0-107.7M-107.6M-89M
20202020-12-31 71K-75M-73.8M-62.2M
20192019-12-31 1.2M-53.8M-50.4M-46.9M
20182018-12-31 2.4M-28.7M-27.1M-20.5M
20172017-12-31 2M-9.1M-9.2M-9.8M
20162016-12-31 589K-6M-6M-5.7M

Every period

Revenue Quarterly

PeriodEndingRevenue
Q2 '262026-06-3025.1M
Q1 '262026-03-3110.7M
Q4 '252025-12-316.2M
Q3 '252025-09-30143K
Q2 '252025-06-301M
Q1 '252025-03-31361K
Q4 '242024-12-310
Q3 '242024-09-300
Q2 '242024-06-30399K
Q1 '242024-03-31640K
Q4 '232023-12-310
Q3 '232023-09-30346K
Q2 '232023-06-30988K
Q1 '232023-03-312.7M
Q3 '222022-09-30458K
Q2 '222022-06-30439K
Q1 '222022-03-313.1M
Q4 '212021-12-310
Q3 '212021-09-300
Q2 '212021-06-300

Gross Profit Quarterly

Revenue minus cost of sales. This filer tags no gross profit of its own..

PeriodEndingGross Profit
Q2 '262026-06-3025M
Q1 '262026-03-3110.5M
Q2 '252025-06-301M
Q1 '252025-03-31361K

Operating Income Quarterly

PeriodEndingOperating Income
Q2 '262026-06-30-132.5M
Q1 '262026-03-31-140.4M
Q4 '252025-12-31-133.7M
Q3 '252025-09-30-142.6M
Q2 '252025-06-30-129.1M
Q1 '252025-03-31-111.4M
Q4 '242024-12-31-94.7M
Q3 '242024-09-30-87.8M
Q2 '242024-06-30-82.8M
Q1 '242024-03-31-73.5M
Q4 '232023-12-31-62.7M
Q3 '232023-09-30-59M
Q2 '232023-06-30-53M
Q1 '232023-03-31-48M
Q4 '222022-12-31-47.6M
Q3 '222022-09-30-43.5M
Q2 '222022-06-30-43M
Q1 '222022-03-31-33.8M
Q4 '212021-12-31-30.9M
Q3 '212021-09-30-27.8M

Net Income Quarterly

PeriodEndingNet Income
Q2 '262026-06-30-120.9M
Q1 '262026-03-31-127.8M
Q4 '252025-12-31-122.8M
Q3 '252025-09-30-130.1M
Q2 '252025-06-30-115.6M
Q1 '252025-03-31-96.8M
Q4 '242024-12-31-80.6M
Q3 '242024-09-30-76.8M
Q2 '242024-06-30-74.1M
Q1 '242024-03-31-66.9M
Q4 '232023-12-31-60.1M
Q3 '232023-09-30-57.5M
Q2 '232023-06-30-51M
Q1 '232023-03-31-46M
Q4 '222022-12-31-45M
Q3 '222022-09-30-41.9M
Q2 '222022-06-30-42.4M
Q1 '222022-03-31-34.6M
Q4 '212021-12-31-30.8M
Q3 '212021-09-30-27.9M

Cost of Revenue Quarterly

PeriodEndingCost of Revenue
Q2 '262026-06-30154K
Q1 '262026-03-31200K
Q2 '252025-06-300
Q1 '252025-03-310

Operating Cash Flow Quarterly

PeriodEndingOperating Cash Flow
Q2 '262026-06-30-94.2M
Q1 '262026-03-31-124.7M
Q4 '252025-12-31-92.9M
Q3 '252025-09-30-110.7M
Q2 '252025-06-30-85.9M
Q1 '252025-03-31-88.5M
Q4 '242024-12-31-66.9M
Q3 '242024-09-30-62.8M
Q2 '242024-06-30-47.6M
Q1 '242024-03-31-52.9M
Q4 '232023-12-31-40.8M
Q3 '232023-09-30-41.3M
Q2 '232023-06-30-45.7M
Q1 '232023-03-31-40.7M
Q4 '222022-12-31-35.2M
Q3 '222022-09-30-38.5M
Q2 '222022-06-30-28M
Q1 '222022-03-31-13.5M
Q4 '212021-12-31-22.9M
Q3 '212021-09-30-25.7M

Free Cash Flow Quarterly

Operating cash flow minus capital expenditure.

PeriodEndingFree Cash Flow
Q2 '262026-06-30-94.7M
Q1 '262026-03-31-125.5M
Q4 '252025-12-31-93.4M
Q3 '252025-09-30-111.6M
Q2 '252025-06-30-89.1M
Q1 '252025-03-31-89.7M
Q4 '242024-12-31-67.9M
Q3 '242024-09-30-63.4M
Q2 '242024-06-30-48.6M
Q1 '242024-03-31-54.2M
Q4 '232023-12-31-41.7M
Q3 '232023-09-30-44.8M
Q2 '232023-06-30-46M
Q1 '232023-03-31-40.7M
Q4 '222022-12-31-35.5M
Q3 '222022-09-30-39.2M
Q2 '222022-06-30-28.6M
Q1 '222022-03-31-13.6M
Q4 '212021-12-31-22.9M
Q3 '212021-09-30-25.8M

Shares Outstanding Quarterly

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

PeriodEndingShares Outstanding
Q2 '262026-06-30105.6M
Q1 '262026-03-31104.1M
Q3 '252025-09-3094.2M
Q2 '252025-06-3093.8M
Q1 '252025-03-3193.1M
Q3 '242024-09-3080.1M
Q2 '242024-06-3079M
Q1 '242024-03-3172.3M
Q3 '232023-09-3056.8M
Q2 '232023-06-3054.3M
Q1 '232023-03-3153.9M
Q3 '222022-09-3053.8M
Q2 '222022-06-3052.5M
Q1 '222022-03-3147.7M
Q3 '212021-09-3038.3M
Q2 '212021-06-3037.1M

EPS TTM

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.

PeriodEndingEPS
Q2 '262026-06-30-5.04
Q1 '262026-03-31-5.13
Q4 '252025-12-31-4.94
Q3 '252025-09-30-4.52
Q2 '252025-06-30-4.10
Q1 '252025-03-31-3.81
Q4 '242024-12-31-3.70
Q3 '242024-09-30-3.71
Q2 '242024-06-30-3.76
Q1 '242024-03-31-3.76
Q4 '232023-12-31-3.68
Q3 '232023-09-30-3.63
Q2 '232023-06-30-3.40
Q1 '232023-03-31-3.27
Q4 '222022-12-31-3.15
Q3 '222022-09-30-2.99
Q2 '222022-06-30-2.94
Q1 '222022-03-31-2.83
Q4 '212021-12-31-2.79
Q3 '212021-09-30-2.78